Anti covid-19 therapies using nucleocapsid and spike proteins

Abstract

Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.

What is claimed is: 
     
         1 . A recombinant yeast comprising a nucleic acid encoding a protein selected from the group consisting of coronavirus 2 (CoV2) nucleocapsid protein, CoV2 spike protein, and a combination thereof. 
     
     
         2 . The recombinant yeast of  claim 1 , wherein the CoV2 nucleocapsid protein has at least 85% identity to SEQ ID NO:1. 
     
     
         3 . The recombinant yeast of  claim 2 , wherein the CoV2 nucleocapsid protein is fused to an N-ETSD having at least 85% identity to SEQ ID NO:2. 
     
     
         4 . The recombinant yeast of  claim 1 , wherein the CoV2 spike protein has at least 85% identity to SEQ ID NO:4. 
     
     
         5 . The recombinant yeast of  claim 4 , wherein the nucleic acid encoding the CoV2 spike protein has at least 99% identity to SEQ ID NO:5. 
     
     
         6 . The recombinant yeast of  claim 1 , wherein the recombinant yeast further comprises a nucleic acid encoding a trafficking sequence, a co-stimulatory molecule, and/or an immune stimulatory cytokine. 
     
     
         7 . The recombinant yeast of  claim 6 , wherein the co-stimulatory molecule is selected from the group consisting of CD80, CD86, CD30, CD40, CD30L, CD40L, ICOS-L, B7-H3, B7-H4, CD70, OX40L, 4-1BBL, GITR-L, TIM-3, TIM-4, CD48, CD58, TL1A, ICAM-1, and LFA3. 
     
     
         8 . The recombinant yeast of  claim 6 , wherein the immune stimulatory cytokine is selected from the group consisting of IL-2, IL-12, IL-15, nogapendekin alfa-imbakicept, IL-21, IPS1, and LMP1. 
     
     
         9 . The method of  claim 1 , wherein the recombinant yeast is  Saccharomyces cerevisiae.    
     
     
         10 . A method for inducing immunity against CoV2 in a patient in need thereof, the method comprising administering to the patient the recombinant yeast of  claim 1 .